Azithromycin showed equivalent efficacy to doxycycline in treating moderate to severe meibomian gland dysfunction, with reduced dosing and potentially fewer gastrointestinal adverse events, a study found.
As reported by the authors, meibomian gland dysfunction (MGD) has a global prevalence of 35.8% and is more common among East Asian people (51.2%), including Thai people (46.2%). The study was carried out at a tertiary referral center in Thailand between September 2018 and May 2022.
The study included 137 eyes of 137 patients. Patients were randomly assigned to receive oral doxycycline 100 mg